WuXi Biologics has secured a five-year contract with Viridian Therapeutics to manufacture and supply commercial batches of its monoclonal antibody veligrotug.
WuXi Biologics has signed at least two new deals with notable US biotechs this year so far, signaling that the service provider is emerging from …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Viridian, awaiting FDA decision, taps WuXi Bio in eye drug supply deal
WuXi Biologics Achieves GMP Release of 18th Drug Product Facility, Advancing Integrated Drug Substance to Drug Product Capabilities
WuXi Vaccines' Drug Substance Facility Receives Brazil ANVISA GMP Certification for Dengue Vaccine Manufacturing
Niowave kicks off construction of $75M radiopharmaceutical isotope plant in Michigan
Eli Lilly to buy three small vaccine developers
Eli Lilly to buy trio of vaccine developers in $3.8bn outlay - Pharmaceutical Technology
Eli Lilly stock edges higher as company plans nearly $4 billion in vaccine deals
Novartis buys Avidity Biosciences as part of broader spending spree
Ambitious Belgian biotech goes shopping in US 'built to be bought' market | Euractiv
Eli Lilly’s $4 Billion Vaccine Bet
Viridian Therapeutics has spent years moving its thyroid eye disease (TED) hopeful, veligrotug, through clinical trials a |…
WuXi Biologics Achieves GMP Release of 18th Drug Product Facility, Advancing Integrated Drug Substance to Drug Product…
A second shot at gene therapy for Huntington's, China's tightening grip on pharma supply chains, and more Readout biotech updates
WuXi Vaccines' Drug Substance Facility Receives Brazil ANVISA GMP Certification for Dengue Vaccine Manufacturing
With phase 3 results that have “exceeded” BioMarin’s expectations, according to R&D chief Greg Friberg, M.D., the California…
After striking radiopharmaceutical supply deals with pharma giants Novartis and AstraZeneca within the last six months, Niowave…
